S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(1.45%) $922.85
USD/EUR
(0.36%) $0.927
USD/NOK
(0.80%) $10.86
USD/GBP
(0.11%) $0.792
USD/RUB
(0.15%) $92.58

Realtime updates for Inhibrx, Inc. [INBX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
50.00%
return 0.12%
SELL
0.00%
return 1.78%
Last Updated28 Mar 2024 @ 16:00

-0.54% $ 34.96

SELL 62422 min ago

@ $37.88

Issued: 14 Feb 2024 @ 09:30


Return: -7.71%


Previous signal: Feb 13 - 09:30


Previous signal: Buy


Return: 2.07 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency...

Stats
Today's Volume 231 800
Average Volume 776 444
Market Cap 1.66B
EPS $0 ( 2024-03-04 )
Next earnings date ( $-1.040 ) 2024-05-13
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -6.83
ATR14 $0.0180 (0.05%)
Insider Trading
Date Person Action Amount type
2024-03-26 Deck Kelly Sell 625 Stock Option (right to buy)
2024-03-26 Deck Kelly Sell 396 Stock Option (right to buy)
2024-03-26 Deck Kelly Sell 1 459 Stock Option (right to buy)
2024-03-26 Deck Kelly Sell 416 Stock Option (right to buy)
2024-03-20 Deck Kelly Sell 16 777 Stock Option (right to buy)
INSIDER POWER
55.56
Last 100 transactions
Buy: 3 248 725 | Sell: 1 114 859

Volume Correlation

Long: -0.22 (neutral)
Short: -0.97 (very strong negative)
Signal:(28.988) Possible Trading Opportunity Present (swing)

Inhibrx, Inc. Correlation

10 Most Positive Correlations
BIOC0.929
NCBS0.92
FSFG0.918
SNPX0.911
SPFI0.906
BGFV0.905
EQBK0.905
SGMA0.904
PDBC0.903
ADTX0.903
10 Most Negative Correlations
GDNR-0.918
BTWN-0.917
EZGO-0.906
LUNA-0.904
BRAC-0.903
MLCO-0.902
MLVF-0.902
AVAC-0.902
CBAY-0.9
IIN-0.899

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Inhibrx, Inc. Correlation - Currency/Commodity

The country flag -0.51
( weak negative )
The country flag -0.60
( weak negative )
The country flag 0.00
( neutral )
The country flag -0.56
( weak negative )
The country flag -0.30
( neutral )
The country flag -0.27
( neutral )

Inhibrx, Inc. Financials

Annual 2023
Revenue: $1.80M
Gross Profit: $609 000 (33.83 %)
EPS: $-5.12
Q4 2023
Revenue: $1.63M
Gross Profit: $1.34M (81.76 %)
EPS: $-1.730
Q3 2023
Revenue: $119 000
Gross Profit: $-185 000 (-155.46 %)
EPS: $-1.100
Q2 2023
Revenue: $30 000.00
Gross Profit: $-701 000 (-2 336.67 %)
EPS: $-1.080

Financial Reports:

No articles found.

Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators